StartsidePTKFY • OTCMKTS
add
PT Kalbe Farma Unsponsored Indonesia ADR
Forrige sluttkurs
14,64 $
Dagsintervall
14,46 $ - 14,46 $
Årsintervall
11,44 $ - 21,16 $
Markedsverdi
56,64 bill. IDR
Gjennomsnittlig volum
85,00
P/E-tall
-
Utbytte
-
Markedsnyheter
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
| (IDR) | sep. 2025info | Endring år til år |
|---|---|---|
Omsetning | 8,91 bill. | 12,62 % |
Driftskostnader | 2,60 bill. | 14,02 % |
Nettoomsetning | 656,41 mrd. | 14,50 % |
Netto resultatmargin | 7,37 | 1,66 % |
Fortjeneste per aksje | 14,44 | 16,36 % |
EBITDA | 1,05 bill. | 16,48 % |
Faktisk avgiftssats | 24,06 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
| (IDR) | sep. 2025info | Endring år til år |
|---|---|---|
Kontant / kortsiktige inv. | 4,20 bill. | −2,69 % |
Totale aktiva | 30,10 bill. | 4,70 % |
Totale passiva | 5,30 bill. | 9,51 % |
Total egenkapital | 24,80 bill. | — |
Utestående aksjer | 45,32 mrd. | — |
P/B-forhold | 0,03 | — |
Avkastning på aktiva | 7,14 % | — |
Avkastning på kapital | 8,47 % | — |
Kontantstrøm
Netto kontantstrøm
| (IDR) | sep. 2025info | Endring år til år |
|---|---|---|
Nettoomsetning | 656,41 mrd. | 14,50 % |
Kontantstrøm fra drift | 875,16 mrd. | −24,23 % |
Kontanter fra investering | −258,39 mrd. | −46,28 % |
Kontanter fra finansiering | −396,06 mrd. | 5,95 % |
Netto kontantstrøm | 245,07 mrd. | −49,14 % |
Fri kontantstrøm | 569,54 mrd. | −24,75 % |
Om
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
Grunnlagt
10. sep. 1966
Nettsted
Ansatte
12 784
